Rauvolfia

Rauvolfia (Rauvolfia serpentina and Related Species)

1. Identity and Botanical Classification

Taxonomy and Nomenclature

Rauvolfia serpentina, commonly called Indian snakeroot, devil pepper, or serpentine wood — and known locally as Sarpagandha or Chandrika — is a species of flowering plant in the family Apocynaceae. The accepted scientific binomial is Rauvolfia serpentina (L.) Benth. ex Kurz; the spelling "Rauwolfia" (with a "w") is frequently encountered in older pharmaceutical literature and is considered an acceptable alternate orthography. Rauwolfia is an important genus of the plant family Apocynaceae. The genus Rauvolfia Plum. ex L. is represented by 74 species with many synonyms, distributed worldwide, especially on the Asian and African continents.

R. serpentina is native to the Indian subcontinent and East Asia (from India to Indonesia). It is a perennial undershrub widely distributed in India in the sub-Himalayan regions up to 1,000 metres (3,300 ft). The plant grows generally in regions with annual rainfall of 200 to 250 cm and at altitudes up to 1,000 m, and it favours deep, fertile soil rich in organic matter.

Among the most commercially and medicinally important species in the genus are:

• Rauvolfia serpentina — Indian snakeroot; primary source of reserpine and ajmaline; native to South and Southeast Asia.
• Rauvolfia vomitoria — African snakeroot or swizzle stick; commonly called African serpent wood, discovered in the 16th century and a well-known medicinal plant of Africa.
• Rauvolfia tetraphylla — four-leaved snakeroot; widely used in traditional medicine and often used as an adulterant or substitute of Rauvolfia serpentina.

A total of seventeen Rauvolfia species have been traditionally explored for various therapeutic applications, of which the roots of R. serpentina and R. vomitoria are used most commonly for the treatment of many diseases.

Morphology

R. serpentina is an erect undershrub with simple leaves. The root is prominent and tuberous, usually branched. The fresh roots possess high alkaloid concentration.

Common Preparations and Dosage Forms

The root is ground into a powder and packaged in this form, or sold in tablets or capsules. It is commonly used in Asian medicine, including the traditional Ayurvedic system native to India. In Western pharmaceutical practice, isolated purified alkaloids — particularly reserpine — have been formulated as oral tablets. Reserpine is marketed under the brand names Serpalan and Serpasil, and is an alkaloid extract from the root of the plant Rauwolfia serpentina. Hydroalcoholic tinctures and standardized whole-root extracts are also employed in herbal practice; when tincture preparations are used, the reserpine-equivalent content should be verified, with the dose calibrated to a known reserpine content.

2. Traditional and Historical Use

Antiquity and Ayurvedic Tradition

The plant was mentioned in Hindu manuscripts as long ago as 1000 BCE. Rauwolfia serpentina, native to the Indian subcontinent and Southeast Asia, has been used for centuries in the traditional medicine systems of Ayurveda and Unani. The roots of this plant have been used for centuries in Ayurvedic medicines under the name sarpagandha and nakuli for the treatment of mental disorders.

Sarpagandha is used in folk medicine in India for centuries to treat a wide variety of maladies, including snake and insect bites, febrile conditions, malaria, abdominal pain, and dysentery. It was also used as a uterine stimulant, febrifuge, and cure for insanity. The plant parts — root and rhizome — have been used since centuries in Ayurvedic medicines for curing a large number of diseases such as high blood pressure, mental agitation, epilepsy, traumas, anxiety, excitement, schizophrenia, sedative insomnia, and insanity.

In Hindu culture, the plant has been used for hundreds of years under the names Sarpagandha (snake repellent) and Chandrá (moon, lunacy). In the Siddha system of medicine of South India, the roots are similarly employed. Extracts of Rauwolfia serpentina have been used medicinally in India for centuries; they were used in traditional Hindu medicine for a variety of conditions, including snakebite, hypertension, insomnia, and insanity.

African Ethnomedicinal Use

Rauvolfia vomitoria's major alkaloid reserpine was the first modern medicine used for hypertension therapy. R. vomitoria was first extracted in 1952 by Swiss chemists and became the first natural neurotropic drug; today this plant remains the source of numerous psychiatric drugs. Indigenous communities across West and Central Africa used bark, root, and leaf preparations of R. vomitoria as an antihypertensive, febrifuge, and remedy for psychotic conditions, though extensive ethnopharmacological documentation of precise preparation methods is more limited compared to the Indian Ayurvedic record.

Entry into Western Medicine

The presence of alkaloidal principles in R. serpentina was first pointed out in 1890 by Greshoff. In 1933, Chopra, Gupta, and Mukherjee reported the hypotensive activity of the material extracted from the plant, and in 1931 Siddiqui and Siddiqui isolated a series of crystalline alkaloids from R. serpentina. In 1952, reserpine — one of several alkaloids in the plant — was isolated from its root and has since been evaluated in Western medicine as one of the most valuable drugs for treating high blood pressure. The alkaloid reserpine was isolated in 1952 and introduced as an antipsychotic in 1954, marking its entry into Western neuropharmacology. Supplementation with Rauwolfia has been performed in Western medicine since the 1950s, primarily for the purpose of treating psychosis.

3. Key Constituents and Active Compounds

Overall Phytochemical Profile

About 287 alkaloids, seven terpenoids, nine flavonoids, and four phenolic acids have been reported in different parts of the forty-three studied Rauvolfia species. The plant contains more than 50 different alkaloids which belong to the monoterpenoid indole alkaloid (MIA) family. Beyond alkaloids, the plant is also known to contain carbohydrates, flavonoids, glycosides, phlobatannins, phenols, resins, saponins, sterols, tannins, and terpenes.

Principal Monoterpene Indole Alkaloids (MIAs)

The major alkaloids are ajmaline, ajmalicine, ajmalimine, deserpidine, indobine, indobinine, reserpine, reserpiline, rescinnamine, rescinnamidine, serpentine, serpentinine, and yohimbine.

• Reserpine — The most pharmacologically prominent alkaloid. Reserpine irreversibly blocks the H⁺-coupled vesicular monoamine transporters, VMAT1 and VMAT2; it is the blockade of neuronal VMAT2 by reserpine that inhibits uptake and reduces stores of the monoamine neurotransmitters norepinephrine, dopamine, serotonin, and histamine in the synaptic vesicles of neurons. The antihypertensive effect results from VMAT2 inhibition in the sympathetic nervous system and chromaffin cells, reducing sympathetic tone and, in turn, reducing blood pressure.
• Ajmaline — An alkaloid found in the root of Rauwolfia serpentina that acts as a sodium channel blocking agent, classified as a Class Ia antiarrhythmic agent. It is used clinically in supraventricular and ventricular tachycardia and extrasystole, particularly in patients suspected of having Brugada syndrome.
• Ajmalicine (Raubasine) — Ajmalicine is used in the treatment of circulatory diseases. Ajmalicine is useful in the treatment of circulatory diseases, functioning as a cerebral vasodilator.
• Rescinnamine — A purified ester alkaloid of the alseroxylon fraction in species of Rauvolfia, related chemically and pharmacologically to reserpine, with similar properties.
• Deserpidine — Deserpidine is an ester alkaloid isolated from Rauvolfia. Like reserpine, it acts as a monoamine-depleting agent and was historically investigated as an antihypertensive. The primary psychoactive components of Rauvolfia appear to be reserpine, rescinnamine, and deserpidine.
• Serpentine — Serpentine is a type II topoisomerase inhibitor that exhibits antipsychotic properties.
• Yohimbine — Present in R. serpentina roots; also found at higher concentrations in Pausinystalia johimbe (yohimbe). It has been used in traditional medicines in the treatment of angina and hypertension, but is more commonly employed in organic and psychogenic impotence, and used as an aphrodisiac.

Biosynthesis

Ajmaline is a class Ia antiarrhythmic drug and diagnostic agent; first isolated in 1931, it is produced by extraction from the root of Rauvolfia serpentina. All major MIAs in Rauvolfia share a biosynthetic origin rooted in the condensation of tryptamine and secologanin to form strictosidine, the universal MIA precursor. Individual downstream pathways then diverge to produce reserpine, ajmaline, ajmalicine, and serpentine through specific enzymatic steps. The ajmalicine scaffold derives from tryptophan converted to tryptamine via secologanin, strictosidine, and cathenamine.

4. Mechanisms of Action

Reserpine: VMAT Inhibition and Monoamine Depletion

Vesicular monoamine transporter 2 (VMAT2) is a proton-monoamine antiporter that is widely expressed in central and peripheral neurons and plays a crucial role in loading monoamine neurotransmitters into secretory vesicles. Reserpine binds to VMAT2 as an intracellular monoamine and thereby produces a competitive inhibition of transport of monoamine into the pre-synaptic storage vesicle. VMAT2 is responsible for transporting cytosolic epinephrine and norepinephrine into presynaptic storage vesicles available in sympathetic nerve terminals. This modulation depletes releasable neuronal monoamine neurotransmitter, leading to decreased peripheral vascular resistance and cardiac output, which further reduces blood pressure.

The later discovery that reserpine is an irreversible and non-specific VMAT1/2 inhibitor provided a mechanistic explanation for the effects of this compound. Because this blockade is irreversible, the duration of reserpine's pharmacological action extends beyond its plasma half-life, persisting until new storage vesicles are synthesized. The primary effect of the major Rauvolfia alkaloids is the blockage of vesicular storage of monoamines, ultimately leading to greater degradation of these neurotransmitters by the MAO enzyme and an overall decrease in neuronal activity in monoamine pathways — thus the overall effect is inhibitory and sedative.

Ajmaline: Sodium Channel Blockade

Classified under the Class Ia antiarrhythmic drugs, ajmaline works by inhibiting sodium channels in the heart, thereby stabilizing the cardiac rhythm. Ajmaline works by changing the shape and threshold of cardiac action potentials through inhibition of various currents, including I_Na, I_to, or I_Kr. It primarily targets the Nav1.5 cardiac sodium channels, and by binding to these channels, ajmaline reduces the influx of sodium ions during the cardiac action potential, prolonging phase 0 depolarization and thereby slowing conduction velocity of electrical impulses in the heart.

5. Scientific Evidence by Area of Use

5.1 Hypertension

Reserpine is an antihypertensive drug that has been used as a first-line drug since the 1940s, and more recently has been used as second-line therapy in the SHEP (1991) and ALLHAT (2002) clinical programs. The reasons for this change in use are not very clear, but it is generally believed that the development of newer antihypertensive medications with better side-effect profiles rendered reserpine less favourable.

A 2016 Cochrane systematic review (Shamon & Perez, Cochrane Library) evaluated dose-related efficacy of reserpine versus placebo or no treatment in primary hypertension. The authors' conclusions stated that reserpine is effective in reducing systolic blood pressure roughly to the same degree as other first-line antihypertensive drugs, though the dose-response pattern could not be determined because of the small number of trials. More randomised controlled trials (RCTs) are needed to assess the effects of reserpine on blood pressure and to determine the dose-related safety profile before the role of this drug in the treatment of primary hypertension can be definitively established.

An early clinical study published in the British Heart Journal (Vakil, 1949) reported on a clinical trial of Rauwolfia serpentina in essential hypertension, representing one of the first systematic Western clinical investigations of the plant. The effect of crude Rauwolfia or its alseroxylon fraction (rauwiloid) was studied in forty patients with hypertension in whom a safe reduction of blood pressure was clinically desirable; thirty-six had severe associated cerebral, renal, or cardiac complications. A maintained reduction of more than 10 mmHg in the average mean arterial pressure occurred in 45% of all patients and in 61.5% of the white patients; an average diastolic pressure of less than 90 mmHg was obtained in 32.5% of the patients.

A 2016 Cochrane review found reserpine to be as effective as other first-line antihypertensive drugs for lowering blood pressure, and reserpine was recommended as an alternate drug for treating hypertension by the JNC 8 Committee. The usual doses studied were 0.05–0.2 mg per day, described as being well tolerated, with the most common adverse effect being nasal stuffiness.

Evidence strength: Moderate. Evidence from multiple clinical trials establishes antihypertensive efficacy comparable to other first-line agents. However, the total number of rigorously designed modern RCTs is limited, and most landmark data derive from mid-20th century trials using higher doses than those now considered appropriate.

5.2 Cardiac Arrhythmias (Ajmaline)

Ajmaline has been reported as an antiarrhythmic compound used for the treatment of Brugada syndrome and the acute treatment of atrial or ventricular tachycardia. The class IA anti-arrhythmic drug ajmaline is used as a diagnostic pharmacological challenge in suspected cases of Brugada syndrome (BrS); however, the mechanism of action is not fully established, and there has long been debate about the precision of its diagnostic effect. A study found that ajmaline elicited a Brugada type I ECG pattern in 27% of atrioventricular nodal re-entrant tachycardia patients and even in 5% of control individuals, indicating that the specificity of the ajmaline challenge is imperfect.

Due to the low bioavailability of ajmaline, a semisynthetic propyl derivative called prajmaline (trade name Neo-gilurythmal) was developed that induces effects similar to those of its predecessor but has better bioavailability and absorption. Hemodynamic studies in animals showed that hemodynamic studies performed in anesthetized and conscious dogs demonstrated no significant changes in measured hemodynamic parameters at doses equal to or less than 2 mg per kilogram.

Evidence strength: Moderate to strong for clinical use in acute arrhythmia management and Brugada syndrome provocation testing. Ajmaline's utility as a diagnostic probe for Brugada syndrome is established in clinical cardiology practice, though specificity concerns warrant careful interpretation.

5.3 Psychiatric Conditions (Antipsychotic / Sedative)

Rauwolfia alkaloids are bioactive compounds derived from the root of the medicinal shrub Rauwolfia serpentina, which has been used in traditional Asian medicine, including Ayurveda native to India, for over 2,000 years to treat insanity and other ailments. Reserpine was introduced to Western medicine in 1952 and was widely prescribed for its antihypertensive and antipsychotic properties. Supplementation with Rauwolfia has been performed in Western medicine since the 1950s primarily for the purpose of treating psychosis; this use has mostly been replaced with the availability of atypical antipsychotic medications, because they are able to successfully treat symptoms of psychosis with fewer risks of motor side effects.

Despite the beneficial effects of reserpine, side effects were described as resembling a parkinsonian syndrome, with symptoms including depression, gastric dysmotility, and extrapyramidal symptoms. Although the molecular target of reserpine was not identified for decades, researchers observed that reserpine depleted dopamine in biological tissue and caused parkinsonism in rats.

Evidence strength: Historically documented but now largely superseded. The clinical evidence from the 1950s–1960s demonstrated antipsychotic efficacy, but high rates of extrapyramidal and depressive side effects led to replacement by newer agents. No large modern RCTs have been conducted for this indication with contemporary trial designs.

5.4 Other Pharmacological Areas Under Investigation

Species R. serpentina, R. tetraphylla, R. verticillata, and R. vomitoria of this genus have been extensively studied for pharmacological activities including antimicrobial, antioxidant, antiprotozoal, antitrypanosomal, antipsychotic, cardioprotective, cholinesterase inhibitory, and hepatoprotective effects. Clinical trials of herbal formulations and extracts of R. serpentina and its MIAs have been reported for CVD, CNS, antihypertensive therapy, antidiabetic effects, and psoriasis therapy, while extracts and phytoconstituents of remaining Rauvolfia species predominantly require additional clinical investigation.

Due to their traditional uses, various extracts and herbal formulations of Rauvolfia species have been marketed without proper assessment of clinical trials and quality control and quality assurance based on major active monoterpene indole alkaloids.

Evidence strength for antimicrobial, antidiabetic, and antiprotozoal effects: Preliminary. Data are predominantly from in vitro and animal studies. Human clinical trial data for these non-cardiovascular, non-psychiatric indications are sparse or absent.

6. Body Systems and Health Areas Associated with Rauvolfia

• Cardiovascular system: Antihypertensive (via reserpine/VMAT2 inhibition); antiarrhythmic (via ajmaline/sodium channel blockade); historical use as cerebral vasodilator (ajmalicine).
• Central nervous system: Sedative and antipsychotic effects (reserpine and serpentine); depletion of central monoamine stores.
• Autonomic nervous system: Sympatholytic activity through peripheral catecholamine depletion.
• Gastrointestinal system: Historical use for abdominal pain, dysentery; adverse effect of increased gastric secretion (hyperchlorhydria) at higher doses.
• Immune / Antimicrobial: In vitro antimicrobial, antiprotozoal, and antitrypanosomal activities reported; no established human clinical evidence.
• Endocrine system: Reserpine stimulates prolactin secretion (hyperprolactinemia), which led to historical concerns about breast cancer (subsequently not confirmed in prospective studies — see Safety section).

7. Dosage Forms and Reported Dosages

The initial clinical trials used high doses of reserpine (0.75 mg to 10 mg daily), which seemed to cause depression and various other gastrointestinal symptoms. Contemporary clinical use employs substantially lower doses. The daily dose of reserpine in antihypertensive treatment is as low as 0.05 to 0.25 mg. The usual doses in more recent evaluations were 0.05–0.2 mg per day.

Other side effects include bradycardia and worsening of asthma with higher doses of 0.5 mg or greater, and there are reports of drowsiness, nightmares, and fatigue.

Later studies showed that depression and hyperchlorhydria produced by reserpine are attributed to its high doses; at low and effective doses, reserpine does not precipitate depression and gastric troubles.

For herbal whole-root preparations, the reserpine content of the preparation determines dosage equivalence. When tincture preparations are used, the dose ranges from an initial 0.5 mg reserpine-equivalent daily to a maintenance range of 0.1–0.5 mg daily, with the reserpine content of each preparation needing to be analytically verified.

For ajmaline (pharmaceutical-grade, intravenous antiarrhythmic use), hemodynamic studies performed in anesthetized and conscious dogs demonstrated no significant changes in measured hemodynamic parameters at doses equal to or less than 2 mg per kilogram — however, human clinical dosing protocols for Brugada challenge testing differ from this animal data and are governed by institutional cardiology protocols not captured in the present literature reviewed.

8. Safety, Adverse Effects, and Drug Interactions

Dose-Dependent Adverse Effects

R. serpentina may cause adverse effects by interacting with various prescription drugs or via interference with mechanisms of mental depression or peptic ulcer. The reserpine in R. serpentina is associated with diverse adverse effects including vomiting, diarrhea, dizziness, headache, anxiety, or hypersensitivity reactions.

VMAT2 inhibition leads to depletion of other monoamines, particularly serotonin, which induces a plethora of nondopaminergic effects including depression, parkinsonism, fatigue, and GI disturbances. Mental depressions were encountered more commonly among patients treated with herbal preparations of R. serpentina than among untreated patients.

Dosage of reserpine is an important factor in the development of depression. Reserpine may also cause hyperprolactinemia, and it passes into breast milk and is harmful to breast-fed infants; it should therefore be avoided during breastfeeding if possible.

The Breast Cancer Question

Oncologic concerns were raised after a large drug surveillance center in Boston reported an association between reserpine — a stimulator of prolactin — and breast cancer in 1974, which was partially but not completely confirmed in two similar centers in Europe. A critical review of these studies elucidated several design flaws. Subsequent, controlled studies failed to show an association between reserpine and an increased incidence of breast carcinoma. A review and pooled analysis of all published case-control studies found a small but significant increase in the risk of breast cancer with reserpine use; however, this finding was not confirmed by prospective studies. The Hypertension Detection and Follow-Up Program (HDFP), which examined 1,036 women receiving reserpine with an average exposure of 1.97 years during a 5-year follow-up, concluded that in this setting there is no indication of the previously postulated association of reserpine and the short-term enhancement of breast tumor growth.

Contraindications

Severe depression and Parkinson's disease are contraindications to Rauwolfia/reserpine use. The irreversible depletion of dopamine stores by reserpine could worsen parkinsonian symptoms, and the monoamine-depleting action of reserpine is contraindicated in patients with pre-existing depressive illness.

Drug Interactions

When prescribing Rauwolfia, care must be taken about potential drug interactions, including with monoamine oxidase (MAO) inhibitors. Because reserpine depletes stored monoamines while MAO inhibitors block their breakdown, co-administration can result in excessive monoamine accumulation or unpredictable CNS and cardiovascular effects. Key herbal-constituent interactions are those potentially affecting SSRIs, beta-adrenergic blockers, and monoamine oxidase inhibitors. Co-administration of reserpine with beta-adrenergic blockers may produce additive bradycardic effects. Addition of reserpine to tricyclic antidepressants or other sympathomimetic agents can produce aberrant cardiovascular responses.

Reserpine acts by depleting catecholamines, including norepinephrine, dopamine, and serotonin, from central and peripheral synapses. This mechanism underlies interactions with any co-administered drug that also modulates monoamine availability.

Conservation Status

Among the six Indian species of the Rauvolfia genus, R. serpentina and R. tetraphylla are particularly valued for their medicinal properties, with R. serpentina facing extinction and listed under CITES Appendix II. R. serpentina is designated "critically endangered" by the Conservation Assessment and Management Plan (CAMP) workshop in Nepal, and its trade is regulated under CITES. In India, it is listed as "critically endangered" in the states of Maharashtra, Chhattisgarh, and Andhra Pradesh, and "vulnerable" in Kerala, Odisha, and Tamil Nadu. The demand for root material for pharmaceutical production has driven significant over-harvesting of wild populations.

Quality Control Concerns

Various extracts and herbal formulations of Rauvolfia species have been marketed without proper assessment of clinical trials and quality control/quality assurance based on major active monoterpene indole alkaloids. Because the potency of whole-root preparations depends directly on the alkaloid content — which varies by species, plant part, geographical origin, and harvest timing — assayed preparations with a known reserpine content are strongly preferred for any clinical application. Quality control and quality assurance of extracts and herbal formulations of Rauvolfia species is analyzed by qualitative and quantitative methods based on major MIAs using HPTLC, HPLC, and HPLC-MS.

References

• Iqbal et al. (2022). Genus Rauvolfia: A review of its ethnopharmacology, phytochemistry, quality control/quality assurance, pharmacological activities and clinical evidence. PubMed (PMID 35504505)
• Shamon SD, Perez MI (2016). Blood pressure-lowering efficacy of reserpine for primary hypertension. Cochrane Database of Systematic Reviews
• Reserpine: A New Consideration of an Old Drug for Refractory Hypertension. PMC (PMC7402223)
• Eiden LE et al. (2016). The vesicular monoamine transporter 2: an underexplored pharmacological target. PMC (PMC5028832)
• Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines. PMC (PMC10770148)
• De novo biosynthesis of antiarrhythmic alkaloid ajmaline. Nature Communications (2024)
• Ajmaline blocks INa and IKr without eliciting differences between Brugada syndrome patient and control human pluripotent stem cell-derived cardiac clusters. PMC (PMC5727153)
• Therapeutic potential of reserpine in metabolic syndrome: An evidence-based study. ScienceDirect / Pharmacological Research (2022)
• Itoh et al. (2005). Indole alkaloids and other constituents of Rauwolfia serpentina. PubMed (PMID 15974606)
• Reserpine — 15th Report on Carcinogens. NCBI Bookshelf / National Toxicology Program
• Curb JD et al. (1982). Reserpine and breast cancer in the Hypertension Detection and Follow-Up Program. PubMed (PMID 7040229)
• Rauvolfia serpentina. Wikipedia
• Reserpine. Wikipedia
• Ajmaline. Wikipedia
• Rauvolfia serpentina — Overview. ScienceDirect Topics
• Ajmaline — Overview. ScienceDirect Topics
• Rauwolfia vomitoria (Apocynaceae): A comprehensive insight into its botany, ethnomedicinal uses, pharmacology, phytochemistry, and clinical trials. ScienceDirect (2025)
• Monachino J (1954). Rauvolfia serpentina — Its history, botany and medical use. Economic Botany, Springer
• Anthropogenic Disturbances and Invasion of Mikania micrantha Threaten Rauvolfia serpentina Populations in Nepal. PMC (PMC12720017)
• Wu et al. (2025). Structural insights into substrate transport and drug inhibition of VMAT2. The FEBS Journal